Curzion Pharmaceuticals Acquired by Horizon Therapeutics
DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
After Change Up Top, Syntonix Inks Boehringer Ingelheim Deal Worth Up to $63M
News | 10. 24. 2005
After a management change over the summer, drug formulation and delivery company Syntonix Pharmaceuticals Inc. has kicked off autumn with a collaboration with Boehringer Ingelheim GmbH that could bring in as much as $63 million.